ClinicalTrials.gg
TerminatedNCT04543409MESSINAUpdated Nov 18, 2023Results posted

A Study of Benralizumab in Patients With Eosinophilic Esophagitis

A Phase 3 interventional study of Benralizumab and Matching placebo in Eosinophilic Esophagitis, sponsored by AstraZeneca. Terminated at 78 sites in 12 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints. Given the lack of clear benefit in this patient population, study has been terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 41 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.

Enrollment
11th of 111
211 · median 36
Started
2020
with 10 others
Phase 3
20 of 165
1 open now
Registered
115th of 165
by date

Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 11th largest by enrollment of the 111 interventional ones that give a count, is one of 11 that started in 2020, is one of 20 in phase 3, and was the 115th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Eosinophilic Esophagitis with a site in United States, or all of them as a file.
02

Study summary

The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a 28-week open-label treatment period). It is proposed that benralizumab will deplete eosinophils from GI tissue(s), improve the symptoms of dysphagia, and improve endoscopy scores as well as other markers of disease activity. Upon completion of the initial 52-week treatment period, patients will be offered an additional Open Label Extension period of at least 1 year, with benralizumab treatment and ongoing study assessments.

03

Conditions studied

  • Eosinophilic Esophagitis

Keywords

  • Eosinophilic Esophagitis
  • EoE
  • Benralizumab
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 12 to 65 years of age, inclusive, at the time of signing the or assent (if applicable) form.
  • Documented previous diagnosis of EoE by endoscopy.
  • Must be symptomatic at Visit 1 (screening) and Visit 2 (randomization):

    1. A patient reported an average of at least 2 days per week with an episode of dysphagia over the 4 weeks prior to Visit 1 AND
    2. An average of at least 2 days per week with an episode of dysphagia (Daily DSQ ≥2) between Visit 1 and Visit 2, and at least 2 days per week with an episode of dysphagia (Daily DSQ ≥2) in each of the 2 weeks immediately prior to randomization
  • May be on background medications for EoE and related treatments during the study as long as the background medications have been stable for at least 4 weeks (8 weeks for PPI) prior to the screening and there is agreement not to change type of background medication or dosage during the run-in period and for the first 52 weeks of the study unless a change is medically indicated.
  • Negative serum pregnancy test for female patients of at Visit1.
  • Women of childbearing potential must agree to use a highly effective form of (confirmed by the Investigator) from randomization throughout the study duration and within 12 weeks after last dose if IP.

Exclusion criteria

Exclusion Criteria:

  • Other GI disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, or celiac disease.
  • Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation during the run-in period.
  • Esophageal dilation performed within 8 weeks prior to screening and prior esophageal surgery that would impact the assessments for EoE
  • Use of a feeding tube, or having a pattern of not eating solid food daily during the run-in period.
  • Hypereosinophilic syndrome, defined by multiple organ involvement and persistent blood eosinophil count >1500 eos/μL.
  • EGPA vasculitis.
  • Eosinophilic gastritis, gastroenteritis, enteritis, or colitis documented by .
  • Current , or history of malignancy with some specific exceptions.
  • History of anaphylaxis to any biologic therapy or vaccine.
  • Current active liver disease:

    • Chronic stable and C (including positive testing for hepatitis B surface antigen [HBsAg] or antibody), or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria.
    • (ALT) or aspartate aminotransferase (AST) level ≥3 times the (ULN), confirmed by repeated testing during the run-in period.
  • Helminth parasitic infection diagnosed within 24 weeks prior to the date or assent (if applicable) is obtained that has not been treated with or has failed to respond to standard of care therapy.
  • History of known immunodeficiency disorder including a positive (HIV) test.
  • Concomitant use of medication.
  • Initiation or change of a food-elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to start of the run-in period.
  • Currently pregnant, breastfeeding, or lactating women.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)

    Biological: Matching placebo

Interventions

  • BiologicalBenralizumab

    Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume

  • BiologicalMatching placebo

    Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With a Histologic Response, Defined as a Peak Esophageal Intraepithelial Eosinophil Count ≤ 6 Eos/Hpf.

    Percentage of patients with a histologic response at Week 24 and Week 52. A histologic response is defined as a peak esophageal intraepithelial eosinophil count \<= 6 eos/hpf across all available esophageal levels. Subjects with no biopsy data at Week 24 or with intercurrent events prior to Week 24 such as changes to background medications or additional new therapies for EoE are considered non-responders. The number analyzed represents the number of participants in the treatment group that could have made it to the timepoint by the data cut off.

    Time frame: Week 24, Week 52

  2. Changes From Baseline in Dysphagia Symptom Questionnaire (DSQ)

    The Dysphagia Symptom Questionnaire (DSQ) captures the presence and severity of dysphagia symptoms in the past day in a 4-item questionnaire. The DSQ score is calculated over 14-day periods and ranges from 0 to 84, with a lower score indicating less severe dysphagia. At least 8 days with evaluable daily score in 14-day period are required; otherwise the DSQ score for the period is set to missing. The number analyzed represents the number of participants with data at that visit (including patients with imputed values post intercurrent events).

    Time frame: Week 24, Week 52

Secondary outcomes

  1. Percent Change From Baseline in Tissue Eosinophils

    Percent change from baseline in tissue eosinophils (eos) at Week 24 and Week 52. The number analyzed represents the number of participants with data at that visit (including imputed values).

    Time frame: Week 24, Week 52

  2. Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Grade Score at Week 24

    EoE-HSS Grade and Stage Scores evaluate eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Total grade score (TGS): mean of the grade score ratios per region. Grade score ratio per region is the sum of all available feature grade scores divided by the maximum possible score. The maximum possible total grade score is 1. The number analyzed represents the number of participants with data at that visit (including imputed values).

    Time frame: Week 24

  3. Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Stage Score at Week 24

    EoE-HSS Grade and Stage Scores evaluate eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Total stage score (TSS): mean of the stage score ratios per region. Stage score ratio per region is the sum of all available feature stage scores divided by the maximum possible score. The maximum possible total stage score is 1. The number analyzed represents the number of participants with data at that visit (including imputed values).

    Time frame: Week 24

  4. Changes From Baseline in Centrally-read Endoscopic Reference Score (EREFS)

    EREFS is a scoring system for assessing the presence and severity of the major endoscopic signs of EoE.The score ranges from 0 (normal) to 9 (severe disease). EREFS total score (TS): The worst score for each individual component from the proximal and distal scores were summed to form the EREFS total score (TS). The number analyzed represents the number of participants with data at that visit (including patients with imputed values post intercurrent events).

    Time frame: Week 24, Week 52

  5. Treatment Responder Rate at Week 24, Defined as a Composite of Histological Response (≤6eos/Hpf) and Clinically Meaningful Improvement From Baseline in Dysphagia Symptom Questionnaire (DSQ) (30% Improvement) at Week 24

    Percentage of participants with a treatment response at Week 24. A treatment response is defined as composite of histologic response and clinically meaningful improvement (30% reduction) from baseline in DSQ score. Participants with missing data at Week 24 or with intercurrent events prior to Week 24 are considered non-responders.

    Time frame: Week 24

  6. Centrally-read Biopsies for Additional Histopathology Including Tissue Eosinophil Counts at Week 24

    Esophagogastroduodenoscopy biopsies were collected at week 24 and sent to the central lab for slide preparation and for central, blinded pathology review of tissue eosinophil counts and histopathology. Centralized slide assessments and scoring from an independent physician review was performed for all biopsies.

    Time frame: Week 24

  7. Dysphagia-free Days as Captured by the Dysphagia Symptom Questionnaire (DSQ)

    Dysphagia free days is a count ranging from 0-28. Higher counts indicate better outcomes. The number analyzed represents the number of participants with data at that visit.

    Time frame: Week 24, Week 52

  8. Frequency of Dysphagia Episodes as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D)

    EoE-3D is a daily diary focused on the patient experience of EoE. Dysphagia episode frequency is summarized as the total number of dysphagia episodes occurring over each 28-day period following randomization, scaled up to 28 days based on missing days. Requires at least 8 days of evaluable data in each 14-day period within each 28-day period; otherwise the period is set to missing. The number analyzed represents the number of participants with data at that visit.

    Time frame: Week 24, Week 52

  9. Changes From Baseline in Dysphagia Associated Pain, Discomfort, and Overall Severity as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D) at Week 24

    In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), patients report on whether they experienced episodes of difficulty swallowing in the past 24 hours and if so, how many. Patients respond to 3 questions on the pain, discomfort, and overall severity of the event using a numeric rating scale (0 \[no\] to 10 \[worst\]). This is repeated for each episode reported. Each category score is calculated as the sum of daily average values in the 14-day period divided by the number of days with available episodes of difficulty swallowing episodes during the same 14-day period (each of the three final scores range from 0 to 10, with higher values indicating a worse outcome in that category). Requires at least 8 days of evaluable data during the period; otherwise, the mean scores are set to missing. Days with 0 episodes of difficulty swallowing count as evaluable. In case all 14 days with 0 episode of difficulty swallowing, the score is set to missing.

    Time frame: Week 24

  10. Changes From Baseline in Dysphagia Associated Pain, Discomfort, and Overall Severity as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D) at Week 52

    In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), patients report on whether they experienced episodes of difficulty swallowing in the past 24 hours and if so, how many. Patients respond to 3 questions on the pain, discomfort, and overall severity of the event using a numeric rating scale (0 \[no\] to 10 \[worst\]). This is repeated for each episode reported. Each category score is calculated as the sum of daily average values in the 14-day period divided by the number of days with available episodes of difficulty swallowing episodes during the same 14-day period (each of the three final scores range from 0 to 10, with higher values indicating a worse outcome in that category). Requires at least 8 days of evaluable data during the period; otherwise, the mean scores are set to missing. Days with 0 episodes of difficulty swallowing count as evaluable. In case all 14 days with 0 episode of difficulty swallowing, the score is set to missing.

    Time frame: Week 52

  11. Changes From Baseline in Abdominal Pain and Nausea as Captured by the Daily Diary at Week 24

    In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), respondents are asked to report the severity of abdominal pain and the severity of nausea at their worst over the past 24 hours using an 11-point numeric rating scale (0 \[no\] to 10 \[worst\]). Abdominal pain severity and nausea severity will be summarized individually as 14-day mean scores. Each 14-day mean score will be calculated as the sum of daily numerical rating scale score responses divided by the number of days with evaluable data in the same 14-day period. Calculation of the 14-day means will require at least 8 out of 14 days of evaluable data; otherwise, the mean score will be set to missing. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).

    Time frame: Week 24

  12. Changes From Baseline in Abdominal Pain and Nausea as Captured by the Daily Diary at Week 52

    In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), respondents are asked to report the severity of abdominal pain and the severity of nausea at their worst over the past 24 hours using an 11-point numeric rating scale (0 \[no\] to 10 \[worst\]). Abdominal pain severity and nausea severity will be summarized individually as 14-day mean scores. Each 14-day mean score will be calculated as the sum of daily numerical rating scale score responses divided by the number of days with evaluable data in the same 14-day period. Calculation of the 14-day means will require at least 8 out of 14 days of evaluable data; otherwise, the mean score will be set to missing. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).

    Time frame: Week 52

  13. Changes From Baseline in the Pediatric Eosinophilic Esophagitis Symptom Severity Module (PEESS)

    The Pediatric Eosinophilic Esophagitis Symptom Severity Module, Version 2, Children and Teens Report (PEESS) is an 18-item assessment of EoE symptom severity and frequency validated for use in patients age 8 to 18 years. The recall period is one month. The first 18 questions alternate between a question about a given symptom's frequency (never=0, almost never=1, sometimes=2, often=3, almost always=4) and a question about the symptom's severity (face rating scale with drawings representing: not bad at all=0, a little bad=1, kind of bad=2, bad=3, very bad=4). The remaining two questions ask about frequency of eating less food than others and frequency of needing more time to eat than others. The overall score ranges from 0 to 80, with higher scores representing more severe and frequent EoE symptoms. The number analyzed represents the number of participants with data at that visit.

    Time frame: Week 24, Week 52

  14. Changes From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EOE-QoL-A) at Week 24

    The Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QoL-A) is a 30-item assessment developed specifically to measure health-related quality of life in patients with EoE. Responses are on a 5-point scale: Not at all = 4, Slightly = 3, Moderately = 2, Quite a Bit = 1, Extremely = 0. The assessment has 5 domains: eating/diet impact, social impact, emotional impact, disease anxiety and swallowing anxiety. Domain scores are calculated as follows: * Eating/Diet Impact (range 0 to 40): sum of Q2, Q9, Q16, Q24, Q25, Q26, Q27, Q28, Q29, Q30 * Social Impact (range 0 to 16): sum of Q14, Q17, Q19, Q22 * Emotional Impact (range 0 to 32): sum of Q1, Q5, Q6, Q7, Q11, Q13, Q21, Q23 * Disease Anxiety (range 0 to 20): sum of Q4, Q10, Q12, Q15, Q18, * Swallowing Anxiety (range 0 to 12): sum of Q3, Q8, Q20 The total score (range 0 to 120) is calculated as the sum of all responses. Lower scores indicate a greater degree of impairment. Higher scores indicate a better quality of life.

    Time frame: Week 24

  15. Changes From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EOE-QoL-A) at Week 52

    The Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QoL-A) is a 30-item assessment developed specifically to measure health-related quality of life in patients with EoE. Responses are on a 5-point scale: Not at all = 4, Slightly = 3, Moderately = 2, Quite a Bit = 1, Extremely = 0. The assessment has 5 domains: eating/diet impact, social impact, emotional impact, disease anxiety and swallowing anxiety. Domain scores are calculated as follows: * Eating/Diet Impact (range 0 to 40): sum of Q2, Q9, Q16, Q24, Q25, Q26, Q27, Q28, Q29, Q30 * Social Impact (range 0 to 16): sum of Q14, Q17, Q19, Q22 * Emotional Impact (range 0 to 32): sum of Q1, Q5, Q6, Q7, Q11, Q13, Q21, Q23 * Disease Anxiety (range 0 to 20): sum of Q4, Q10, Q12, Q15, Q18, * Swallowing Anxiety (range 0 to 12): sum of Q3, Q8, Q20 The total score (range 0 to 120) is calculated as the sum of all responses. Lower scores indicate a greater degree of impairment. Higher scores indicate a better quality of life.

    Time frame: Week 52

  16. Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) at Week 24

    The Short Form 36-item Health Survey, version 2, acute recall (SF-36v2) is a 36-item, self-report survey of functional health and well-being, with a 1-week recall period. There are 8 domain scores: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health Perceptions (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Problems (RE), and Mental Health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) were computed from subscale scores to give a broader metric of physical and mental health-related quality of life. All scores range from 0-100, with higher scores meaning better outcomes. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).

    Time frame: Week 24

  17. Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) at Week 52

    The Short Form 36-item Health Survey, version 2, acute recall (SF-36v2) is a 36-item, self-report survey of functional health and well-being, with a 1-week recall period. There are 8 domain scores: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health Perceptions (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Problems (RE), and Mental Health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) were computed from subscale scores to give a broader metric of physical and mental health-related quality of life. All scores range from 0-100, with higher scores meaning better outcomes. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).

    Time frame: Week 52

  18. Percent of Patients With Relevant Concomitant Procedures and Healthcare Resource Utilization at Week 24 and Week 52.

    Percent of patients with any relevant concomitant procedures or healthcare resource utilization for Eosinophilic esophagitis (EoE) or an EoE-related episode (e.g., an intervention for food impaction or stricture requiring dilatation) since last healthcare resource utilization assessment during the previous scheduled visit. Assessed at Week 24 and Week 52.

    Time frame: Week 24, Week 52

  19. Patient Reported Overall Severity of Disease as Measured by Patient Global Impression of Severity (PGI-S) at Week 24

    Patient Global Impression of Severity (PGI-S) is an assessment of the patient's perceived disease severity. The answer options are "no symptoms," "very mild," "mild," "moderate," "severe," and "very severe." The number analyzed represents the participants with evaluable PGI-S results at that timepoint.

    Time frame: Week 24

  20. Patient Reported Overall Severity of Disease as Measured by Patient Global Impression of Severity (PGI-S) at Week 52

    Patient Global Impression of Severity (PGI-S) is an assessment of the patient's perceived disease severity. The answer options are "no symptoms," "very mild," "mild," "moderate," "severe," and "very severe." The number analyzed represents the participants with evaluable PGI-S results at that timepoint.

    Time frame: Week 52

  21. Patient Reported Change in Health Status Since Baseline as Measured by Patient Global Impression of Change (PGI-C) at Week 24

    Patient Global Impression of Change (PGI-C) measures the patient's overall impression of response to treatment since the initial dose. The answer options are "much better," "moderately better," "a little better," "about the same/no change," "a little worse," "moderately worse," and "much worse." The number analyzed represents the participants with evaluable PGI-C results at that timepoint.

    Time frame: Week 24

  22. Patient Reported Change in Health Status Since Baseline as Measured by Patient Global Impression of Change (PGI-C) at Week 52

    Patient Global Impression of Change (PGI-C) measures the patient's overall impression of response to treatment since the initial dose. The answer options are "much better," "moderately better," "a little better," "about the same/no change," "a little worse," "moderately worse," and "much worse." The number analyzed represents the participants with evaluable PGI-C results at that timepoint.

    Time frame: Week 52

Other outcomes

  1. Benralizumab Pharmacokinetics

    Serum concentrations of benralizumab through Week 52. Geometric mean calculated using log transformed data.

    Time frame: Up to week 52

  2. Immunogenicity of Benralizumab in Double Blind Period

    Immunogenicity of benralizumab assessed by ADA and nAb in the Double Blind period.

    Time frame: Up to Week 24

  3. Immunogenicity of Benralizumab in Double Blind + Open Label Periods

    Immunogenicity of benralizumab assessed by ADA and nAb in the Double Blind and Open Label periods.

    Time frame: Up to Week 52

  4. Safety and Tolerability in Double Blind Period

    Percentage of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Double Blind treatment period (up to Week 24).

    Time frame: Up to Week 24

  5. Safety and Tolerability in the Open Label Period

    Percentage of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Open Label treatment period (past week 24).

    Time frame: From Week 24 up to Week 52

07

Results

Posted Nov 18, 2023

Participant flow

A total of 404 participants were screened between 22SEP2020 and 22FEB2022. Of those, 211 were randomized to either the treatment (104 participants) or placebo (107 participants) arms of the double-blind treatment period. One participant, who did not meet inclusion/exclusion criteria, was incorrectly randomized but not dosed. Therefore, 103 participants started in the treatment arm and 107 in the placebo arm, for a total of 210 participants.

Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestoneBenralizumabPlacebo
Started103107
Completed101106
Not completed21
Withdrew: Withdrawal by subject11
Withdrew: Subject perceives the ip to be ineffective.10
Open-Label Treatment Period
Participant flow — Open-Label Treatment Period
MilestoneBenralizumabPlacebo
Started100105
Completed7982
Not completed2123
Withdrew: Lost to follow-up01
Withdrew: Study terminated by sponsor1719
Withdrew: Withdrawal by subject43
Open-Label Extension Treatment Period
Participant flow — Open-Label Extension Treatment Period
MilestoneBenralizumabPlacebo
Started4548
Completed00
Not completed4548
Withdrew: Adverse event01
Withdrew: Lost to follow-up10
Withdrew: Study terminated by sponsor4444
Withdrew: Withdrawal by subject01
Withdrew: Unable to schedule gastroscopy01
Withdrew: No study/treatment discontinuation information01

Outcome measures

PrimaryPercentage of Patients With a Histologic Response, Defined as a Peak Esophageal Intraepithelial Eosinophil Count ≤ 6 Eos/Hpf.

Percentage of patients with a histologic response at Week 24 and Week 52. A histologic response is defined as a peak esophageal intraepithelial eosinophil count \<= 6 eos/hpf across all available esophageal levels. Subjects with no biopsy data at Week 24 or with intercurrent events prior to Week 24 such as changes to background medications or additional new therapies for EoE are considered non-responders. The number analyzed represents the number of participants in the treatment group that could have made it to the timepoint by the data cut off.

Time frame:
Week 24, Week 52
Reported as:
Number · Percentage of Participants
Percentage of Patients With a Histologic Response, Defined as a Peak Esophageal Intraepithelial Eosinophil Count ≤ 6 Eos/Hpf.
Percentage of ParticipantsBenralizumabPlacebo
Week 2487.4 (80.97 to 93.79)6.5 (1.86 to 11.23)
Week 5282.6 (71.66 to 93.56)89.4 (80.55 to 98.18)
Statistical analysis
  • Benralizumab vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 117.49 · 95% CI 38.17 to 361.64The OR estimate and p-value was obtained from the CMH test controlling for region (North America and Rest of the world), baseline steroid use, and presence of strictures at baseline. Odds ratio values \>1 favor Benra 30 mg treatment group.
PrimaryChanges From Baseline in Dysphagia Symptom Questionnaire (DSQ)

The Dysphagia Symptom Questionnaire (DSQ) captures the presence and severity of dysphagia symptoms in the past day in a 4-item questionnaire. The DSQ score is calculated over 14-day periods and ranges from 0 to 84, with a lower score indicating less severe dysphagia. At least 8 days with evaluable daily score in 14-day period are required; otherwise the DSQ score for the period is set to missing. The number analyzed represents the number of participants with data at that visit (including patients with imputed values post intercurrent events).

Time frame:
Week 24, Week 52
Reported as:
Least squares mean · Score
Changes From Baseline in Dysphagia Symptom Questionnaire (DSQ)
ScoreBenralizumabPlacebo
Week 24-12.102 (-16.05 to -8.15)-15.101 (-19.02 to -11.19)
Week 52-19.409 (-25.65 to -13.17)-19.806 (-25.70 to -13.91)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = 0.1770 · Difference in least squares means: 2.999 · 95% CI -1.36 to 7.35Model: Change from baseline in DSQ = Treatment + baseline DSQ + Region + Baseline steroid use + Presence of strictures at baseline.
SecondaryPercent Change From Baseline in Tissue Eosinophils

Percent change from baseline in tissue eosinophils (eos) at Week 24 and Week 52. The number analyzed represents the number of participants with data at that visit (including imputed values).

Time frame:
Week 24, Week 52
Reported as:
Least squares mean · Percentage of change
Percent Change From Baseline in Tissue Eosinophils
Percentage of changeBenralizumabPlacebo
Week 24-94.8 (-100.00 to -82.45)1.4 (-11.75 to 14.60)
Week 52-85.0 (-100.00 to -62.50)-88.6 (-100.00 to -73.67)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = <0.0001 · Difference in least squares means: -96.2 · 95% CI -114.53 to -77.85Model: Percent change from baseline in Peak Esophageal intraepithelial eos counts = Treatment + baseline Peak Esophageal intraepithelial eos counts.
SecondaryChange From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Grade Score at Week 24

EoE-HSS Grade and Stage Scores evaluate eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Total grade score (TGS): mean of the grade score ratios per region. Grade score ratio per region is the sum of all available feature grade scores divided by the maximum possible score. The maximum possible total grade score is 1. The number analyzed represents the number of participants with data at that visit (including imputed values).

Time frame:
Week 24
Reported as:
Least squares mean · Grade Score Ratio Change
Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Grade Score at Week 24
Grade Score Ratio ChangeBenralizumabPlacebo
Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Grade Score at Week 24-0.264 (-0.297 to -0.232)-0.089 (-0.122 to -0.056)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = <0.0001 · Difference in least squares means: -0.175 · 95% CI -0.21 to -0.14Change from baseline in EoE-HSS TGS = Treatment + baseline EoE-HSS grade score + Region + Baseline steroid use + Presence of strictures at baseline
SecondaryChange From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Stage Score at Week 24

EoE-HSS Grade and Stage Scores evaluate eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Total stage score (TSS): mean of the stage score ratios per region. Stage score ratio per region is the sum of all available feature stage scores divided by the maximum possible score. The maximum possible total stage score is 1. The number analyzed represents the number of participants with data at that visit (including imputed values).

Time frame:
Week 24
Reported as:
Least squares mean · Grade Score Ratio Change
Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Stage Score at Week 24
Grade Score Ratio ChangeBenralizumabPlacebo
Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Stage Score at Week 24-0.199 (-0.228 to -0.169)-0.077 (-0.107 to -0.046)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = <0.0001 · Difference in least squares means: -0.122 · 95% CI -0.16 to -0.09Change from baseline in EoE-HSS TSS = Treatment + baseline EoE-HSS stage score + Region + Baseline steroid use + Presence of strictures at baseline
SecondaryChanges From Baseline in Centrally-read Endoscopic Reference Score (EREFS)

EREFS is a scoring system for assessing the presence and severity of the major endoscopic signs of EoE.The score ranges from 0 (normal) to 9 (severe disease). EREFS total score (TS): The worst score for each individual component from the proximal and distal scores were summed to form the EREFS total score (TS). The number analyzed represents the number of participants with data at that visit (including patients with imputed values post intercurrent events).

Time frame:
Week 24, Week 52
Reported as:
Least squares mean · Score
Changes From Baseline in Centrally-read Endoscopic Reference Score (EREFS)
ScoreBenralizumabPlacebo
Week 24-0.5 (-0.91 to -0.10)-0.4 (-0.85 to -0.01)
Week 52-0.3 (-0.9 to 0.32)-0.7 (-1.35 to -0.09)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = 0.7322 · Difference in least squares means: -0.1 · 95% CI -0.52 to 0.32Model: Change from baseline in EREFS TS = Treatment + baseline EREFS TS + Region + Baseline steroid use + Presence of strictures at baseline
SecondaryTreatment Responder Rate at Week 24, Defined as a Composite of Histological Response (≤6eos/Hpf) and Clinically Meaningful Improvement From Baseline in Dysphagia Symptom Questionnaire (DSQ) (30% Improvement) at Week 24

Percentage of participants with a treatment response at Week 24. A treatment response is defined as composite of histologic response and clinically meaningful improvement (30% reduction) from baseline in DSQ score. Participants with missing data at Week 24 or with intercurrent events prior to Week 24 are considered non-responders.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Treatment Responder Rate at Week 24, Defined as a Composite of Histological Response (≤6eos/Hpf) and Clinically Meaningful Improvement From Baseline in Dysphagia Symptom Questionnaire (DSQ) (30% Improvement) at Week 24
Percentage of ParticipantsBenralizumabPlacebo
Treatment Responder Rate at Week 24, Defined as a Composite of Histological Response (≤6eos/Hpf) and Clinically Meaningful Improvement From Baseline in Dysphagia Symptom Questionnaire (DSQ) (30% Improvement) at Week 2443.7 (34.11 to 53.27)4.7 (0.67 to 8.67)
Statistical analysis
  • Benralizumab vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 15.86 · 95% CI 5.79 to 43.47Controlling for region (North America and Rest of the world), baseline steroid use, and presence of strictures at baseline. OR values \>1 would favor Benra 30 mg treatment group.
SecondaryCentrally-read Biopsies for Additional Histopathology Including Tissue Eosinophil Counts at Week 24

Esophagogastroduodenoscopy biopsies were collected at week 24 and sent to the central lab for slide preparation and for central, blinded pathology review of tissue eosinophil counts and histopathology. Centralized slide assessments and scoring from an independent physician review was performed for all biopsies.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Centrally-read Biopsies for Additional Histopathology Including Tissue Eosinophil Counts at Week 24
ParticipantsBenralizumabPlacebo
<1 eos/hpf840
1 to <=6 eos/hpf67
7 to <15 eos/hpf23
15 to <60 eos/hpf033
>=60 eos/hpf256
SecondaryDysphagia-free Days as Captured by the Dysphagia Symptom Questionnaire (DSQ)

Dysphagia free days is a count ranging from 0-28. Higher counts indicate better outcomes. The number analyzed represents the number of participants with data at that visit.

Time frame:
Week 24, Week 52
Reported as:
Mean · Days
Dysphagia-free Days as Captured by the Dysphagia Symptom Questionnaire (DSQ)
DaysBenralizumabPlacebo
Week 2412.65 ± 10.58916.32 ± 11.286
Week 5219.33 ± 10.95020.80 ± 10.472
SecondaryFrequency of Dysphagia Episodes as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D)

EoE-3D is a daily diary focused on the patient experience of EoE. Dysphagia episode frequency is summarized as the total number of dysphagia episodes occurring over each 28-day period following randomization, scaled up to 28 days based on missing days. Requires at least 8 days of evaluable data in each 14-day period within each 28-day period; otherwise the period is set to missing. The number analyzed represents the number of participants with data at that visit.

Time frame:
Week 24, Week 52
Reported as:
Mean · Ratio of Episodes per 28 Day period
Frequency of Dysphagia Episodes as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D)
Ratio of Episodes per 28 Day periodBenralizumabPlacebo
Week 2420.3 ± 28.0513.8 ± 19.15
Week 526.8 ± 11.596.2 ± 9.83
SecondaryChanges From Baseline in Dysphagia Associated Pain, Discomfort, and Overall Severity as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D) at Week 24

In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), patients report on whether they experienced episodes of difficulty swallowing in the past 24 hours and if so, how many. Patients respond to 3 questions on the pain, discomfort, and overall severity of the event using a numeric rating scale (0 \[no\] to 10 \[worst\]). This is repeated for each episode reported. Each category score is calculated as the sum of daily average values in the 14-day period divided by the number of days with available episodes of difficulty swallowing episodes during the same 14-day period (each of the three final scores range from 0 to 10, with higher values indicating a worse outcome in that category). Requires at least 8 days of evaluable data during the period; otherwise, the mean scores are set to missing. Days with 0 episodes of difficulty swallowing count as evaluable. In case all 14 days with 0 episode of difficulty swallowing, the score is set to missing.

Time frame:
Week 24
Reported as:
Least squares mean · Scores per day
Changes From Baseline in Dysphagia Associated Pain, Discomfort, and Overall Severity as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D) at Week 24
Scores per dayBenralizumabPlacebo
Dysphagia-related pain-0.452 (-0.86 to -0.05)-0.412 (-0.84 to 0.02)
Dysphagia-related discomfort-0.370 (-0.73 to -0.01)-0.189 (-0.57 to 0.19)
Overall episode severity-0.481 (-0.83 to -0.13)-0.137 (-0.51 to 0.24)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = 0.8656 · Difference in least squares means: -0.040 · 95% CI -0.50 to 0.42Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline.
  • Benralizumab vs Placebo · ANCOVA · p = 0.3926 · Difference in least squares means: -0.181 · 95% CI -0.60 to 0.23Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline.
  • Benralizumab vs Placebo · ANCOVA · p = 0.0867 · Difference in least squares means: -0.344 · 95% CI -0.74 to 0.05Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
SecondaryChanges From Baseline in Dysphagia Associated Pain, Discomfort, and Overall Severity as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D) at Week 52

In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), patients report on whether they experienced episodes of difficulty swallowing in the past 24 hours and if so, how many. Patients respond to 3 questions on the pain, discomfort, and overall severity of the event using a numeric rating scale (0 \[no\] to 10 \[worst\]). This is repeated for each episode reported. Each category score is calculated as the sum of daily average values in the 14-day period divided by the number of days with available episodes of difficulty swallowing episodes during the same 14-day period (each of the three final scores range from 0 to 10, with higher values indicating a worse outcome in that category). Requires at least 8 days of evaluable data during the period; otherwise, the mean scores are set to missing. Days with 0 episodes of difficulty swallowing count as evaluable. In case all 14 days with 0 episode of difficulty swallowing, the score is set to missing.

Time frame:
Week 52
Reported as:
Least squares mean · Scores per day
Changes From Baseline in Dysphagia Associated Pain, Discomfort, and Overall Severity as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D) at Week 52
Scores per dayBenralizumabPlacebo
Dysphagia-related pain-0.511 (-1.40 to 0.38)-0.776 (-1.65 to 0.10)
Dysphagia-related discomfort-0.456 (-1.14 to 0.22)-0.625 (-1.30 to 0.05)
Overall episode severity-0.522 (-1.26 to 0.22)-0.732 (-1.48 to 0.02)
SecondaryChanges From Baseline in Abdominal Pain and Nausea as Captured by the Daily Diary at Week 24

In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), respondents are asked to report the severity of abdominal pain and the severity of nausea at their worst over the past 24 hours using an 11-point numeric rating scale (0 \[no\] to 10 \[worst\]). Abdominal pain severity and nausea severity will be summarized individually as 14-day mean scores. Each 14-day mean score will be calculated as the sum of daily numerical rating scale score responses divided by the number of days with evaluable data in the same 14-day period. Calculation of the 14-day means will require at least 8 out of 14 days of evaluable data; otherwise, the mean score will be set to missing. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).

Time frame:
Week 24
Reported as:
Least squares mean · Scores per day
Changes From Baseline in Abdominal Pain and Nausea as Captured by the Daily Diary at Week 24
Scores per dayBenralizumabPlacebo
Abdominal pain severity-0.549 (-0.94 to -0.16)-0.815 (-1.20 to -0.53)
Nausea severity-0.524 (-0.90 to -0.15)-0.820 (-1.19 to -0.45)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = 0.2248 · Difference in least squares means: 0.267 · 95% CI -0.16 to 0.70Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline.
  • Benralizumab vs Placebo · ANCOVA · p = 0.1575 · Difference in least squares means: 0.296 · 95% CI -0.11 to 0.71Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
SecondaryChanges From Baseline in Abdominal Pain and Nausea as Captured by the Daily Diary at Week 52

In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), respondents are asked to report the severity of abdominal pain and the severity of nausea at their worst over the past 24 hours using an 11-point numeric rating scale (0 \[no\] to 10 \[worst\]). Abdominal pain severity and nausea severity will be summarized individually as 14-day mean scores. Each 14-day mean score will be calculated as the sum of daily numerical rating scale score responses divided by the number of days with evaluable data in the same 14-day period. Calculation of the 14-day means will require at least 8 out of 14 days of evaluable data; otherwise, the mean score will be set to missing. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).

Time frame:
Week 52
Reported as:
Least squares mean · Scores per day
Changes From Baseline in Abdominal Pain and Nausea as Captured by the Daily Diary at Week 52
Scores per dayBenralizumabPlacebo
Abdominal pain severity-0.826 (-1.44 to -0.22)-1.039 (-1.62 to -0.46)
Nausea severity-0.855 (-1.43 to -0.28)-0.960 (-1.50 to -0.42)
SecondaryChanges From Baseline in the Pediatric Eosinophilic Esophagitis Symptom Severity Module (PEESS)

The Pediatric Eosinophilic Esophagitis Symptom Severity Module, Version 2, Children and Teens Report (PEESS) is an 18-item assessment of EoE symptom severity and frequency validated for use in patients age 8 to 18 years. The recall period is one month. The first 18 questions alternate between a question about a given symptom's frequency (never=0, almost never=1, sometimes=2, often=3, almost always=4) and a question about the symptom's severity (face rating scale with drawings representing: not bad at all=0, a little bad=1, kind of bad=2, bad=3, very bad=4). The remaining two questions ask about frequency of eating less food than others and frequency of needing more time to eat than others. The overall score ranges from 0 to 80, with higher scores representing more severe and frequent EoE symptoms. The number analyzed represents the number of participants with data at that visit.

Time frame:
Week 24, Week 52
Reported as:
Mean · Score
Changes From Baseline in the Pediatric Eosinophilic Esophagitis Symptom Severity Module (PEESS)
ScoreBenralizumabPlacebo
Week 24-0.8 ± 11.69-5.9 ± 14.24
Week 52-6.5 ± 18.04-12.5 ± 15.67
SecondaryChanges From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EOE-QoL-A) at Week 24

The Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QoL-A) is a 30-item assessment developed specifically to measure health-related quality of life in patients with EoE. Responses are on a 5-point scale: Not at all = 4, Slightly = 3, Moderately = 2, Quite a Bit = 1, Extremely = 0. The assessment has 5 domains: eating/diet impact, social impact, emotional impact, disease anxiety and swallowing anxiety. Domain scores are calculated as follows: * Eating/Diet Impact (range 0 to 40): sum of Q2, Q9, Q16, Q24, Q25, Q26, Q27, Q28, Q29, Q30 * Social Impact (range 0 to 16): sum of Q14, Q17, Q19, Q22 * Emotional Impact (range 0 to 32): sum of Q1, Q5, Q6, Q7, Q11, Q13, Q21, Q23 * Disease Anxiety (range 0 to 20): sum of Q4, Q10, Q12, Q15, Q18, * Swallowing Anxiety (range 0 to 12): sum of Q3, Q8, Q20 The total score (range 0 to 120) is calculated as the sum of all responses. Lower scores indicate a greater degree of impairment. Higher scores indicate a better quality of life.

Time frame:
Week 24
Reported as:
Least squares mean · Score
Changes From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EOE-QoL-A) at Week 24
ScoreBenralizumabPlacebo
Eating/Diet Impact1.370 (-0.27 to 3.01)1.169 (-0.46 to 2.79)
Social Impact1.095 (0.21 to 1.98)0.948 (0.07 to 1.83)
Emotional Impact0.912 (-0.46 to 2.29)0.902 (-0.46 to 2.27)
Disease Anxiety0.185 (-0.77 to 1.14)-0.201 (-1.15 to 0.75)
Swallowing Anxiety0.443 (-0.23 to 1.12)0.605 (-0.06 to 1.27)
Total Score4.380 (-0.36 to 9.12)3.362 (-1.33 to 8.06)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = 0.8239 · Difference in least squares means: 0.202 · 95% CI -1.57 to 1.98Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline.
  • Benralizumab vs Placebo · ANCOVA · p = 0.7623 · Difference in least squares means: 0.147 · 95% CI -0.80 to 1.10Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.9898 · Difference of least squares means: 0.010 · 95% CI -1.47 to 1.49Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.4603 · Difference in least squares means: 0.386 · 95% CI -0.64 to 1.41Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.6613 · Difference in least squares means: -0.162 · 95% CI -0.89 to 0.56Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.6965 · Difference in least squares means: 1.017 · 95% CI -4.09 to 6.13Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
SecondaryChanges From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EOE-QoL-A) at Week 52

The Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QoL-A) is a 30-item assessment developed specifically to measure health-related quality of life in patients with EoE. Responses are on a 5-point scale: Not at all = 4, Slightly = 3, Moderately = 2, Quite a Bit = 1, Extremely = 0. The assessment has 5 domains: eating/diet impact, social impact, emotional impact, disease anxiety and swallowing anxiety. Domain scores are calculated as follows: * Eating/Diet Impact (range 0 to 40): sum of Q2, Q9, Q16, Q24, Q25, Q26, Q27, Q28, Q29, Q30 * Social Impact (range 0 to 16): sum of Q14, Q17, Q19, Q22 * Emotional Impact (range 0 to 32): sum of Q1, Q5, Q6, Q7, Q11, Q13, Q21, Q23 * Disease Anxiety (range 0 to 20): sum of Q4, Q10, Q12, Q15, Q18, * Swallowing Anxiety (range 0 to 12): sum of Q3, Q8, Q20 The total score (range 0 to 120) is calculated as the sum of all responses. Lower scores indicate a greater degree of impairment. Higher scores indicate a better quality of life.

Time frame:
Week 52
Reported as:
Least squares mean · Score
Changes From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EOE-QoL-A) at Week 52
ScoreBenralizumabPlacebo
Eating/Diet Impact1.408 (-1.01 to 3.83)1.949 (-0.32 to 4.21)
Social Impact1.462 (0.09 to 2.83)1.984 (0.70 to 3.27)
Emotional Impact1.768 (-0.21 to 3.75)2.451 (0.58 to 4.33)
Disease Anxiety1.063 (-0.43 to 2.56)1.152 (-0.27 to 2.57)
Swallowing Anxiety0.677 (-0.37 to 1.72)1.085 (0.10 to 2.07)
Total Score6.749 (-0.35 to 13.84)8.714 (2.03 to 15.40)
SecondaryChange From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) at Week 24

The Short Form 36-item Health Survey, version 2, acute recall (SF-36v2) is a 36-item, self-report survey of functional health and well-being, with a 1-week recall period. There are 8 domain scores: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health Perceptions (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Problems (RE), and Mental Health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) were computed from subscale scores to give a broader metric of physical and mental health-related quality of life. All scores range from 0-100, with higher scores meaning better outcomes. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).

Time frame:
Week 24
Reported as:
Least squares mean · Score
Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) at Week 24
ScoreBenralizumabPlacebo
Physical functioning (PF)0.2 (-1.36 to 1.70)0.5 (-0.98 to 1.97)
Role limitations due to physical health (RP)0.5 (-1.03 to 2.10)1.5 (-0.06 to 2.99)
Bodily pain (BP)-0.6 (-2.92 to 1.82)0.2 (-2.07 to 2.53)
General health perceptions (GH)-0.9 (-2.62 to 0.78)-0.9 (-2.54 to 0.76)
Vitality (VT)-0.5 (-2.47 to 1.54)-0.5 (-2.50 to 1.48)
Social functioning (SF)-1.5 (-3.84 to 0.92)0.1 (-2.26 to 2.39)
Role limitations due to emotional problems (RE)-1.1 (-3.68 to 1.51)-0.4 (-2.95 to 2.15)
Mental health (MH)-1.7 (-3.83 to 0.51)-0.8 (-2.91 to 1.31)
Psychometrically-based physical summary score (PCS)0.4 (-1.21 to 2.01)0.8 (-0.75 to 2.34)
Mental health component summary scores (MCS)-1.8 (-4.10 to 0.53)-1.2 (-3.44 to 1.11)
Statistical analysis
  • Benralizumab vs Placebo · ANCOVA · p = 0.6852 · Difference in least squares means: -0.3 · 95% CI -1.93 to 1.27Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline.
  • Benralizumab vs Placebo · ANCOVA · p = 0.2685 · Difference in least squares means: -0.9 · 95% CI -2.57 to 0.72Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.5380 · Difference in least squares means: -0.8 · 95% CI -3.27 to 1.71Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.9734 · Difference in least squares means: -0.0 · 95% CI -1.81 to 1.75Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline.
  • Benralizumab vs Placebo · ANCOVA · p = 0.9653 · Difference in least squares means: 0.0 · 95% CI -2.09 to 2.19Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.2326 · Difference in least squares means: -1.5 · 95% CI -4.04 to 0.98Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.6274 · Difference in least squares means: -0.7 · 95% CI -3.44 to 2.08Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.4599 · Difference in least squares means: -0.9 · 95% CI -3.14 to 1.42Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.6456 · Difference in least squares means: -0.4 · 95% CI -2.07 to 1.28Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline
  • Benralizumab vs Placebo · ANCOVA · p = 0.6206 · Difference in least squares means: -0.6 · 95% CI -3.08 to 1.84Model: Change from baseline item score = Treatment + baseline item score + Region + Baseline steroid use + Presence of strictures at baseline.
SecondaryChange From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) at Week 52

The Short Form 36-item Health Survey, version 2, acute recall (SF-36v2) is a 36-item, self-report survey of functional health and well-being, with a 1-week recall period. There are 8 domain scores: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health Perceptions (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Problems (RE), and Mental Health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) were computed from subscale scores to give a broader metric of physical and mental health-related quality of life. All scores range from 0-100, with higher scores meaning better outcomes. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).

Time frame:
Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) at Week 52
ScoreBenralizumabPlacebo
Physical functioning (PF)0.3 (-1.86 to 2.51)0.4 (-1.60 to 2.46)
Role limitations due to physical health (RP)-0.5 (-3.27 to 2.20)0.9 (-1.63 to 3.51)
Bodily pain (BP)0.6 (-2.69 to 3.97)1.8 (-1.34 to 5.00)
General health perceptions (GH)2.3 (-0.71 to 5.39)0.7 (-2.17 to 3.59)
Vitality (VT)-0.2 (-2.69 to 2.31)-2.0 (-4.42 to 0.44)
Social functioning (SF)0.2 (-3.73 to 4.17)-0.5 (-4.26 to 3.34)
Role limitations due to emotional problems (RE)-0.1 (-3.30 to 3.19)-0.3 (-3.39 to 2.76)
Mental health (MH)1.2 (-1.37 to 3.69)-1.1 (-3.46 to 1.30)
Psychometrically-based physical summary score (PCS)0.5 (-2.15 to 3.18)1.4 (-1.15 to 3.85)
Mental health component summary scores (MCS)0.5 (-2.44 to 3.50)-1.9 (-4.78 to 0.89)
SecondaryPercent of Patients With Relevant Concomitant Procedures and Healthcare Resource Utilization at Week 24 and Week 52.

Percent of patients with any relevant concomitant procedures or healthcare resource utilization for Eosinophilic esophagitis (EoE) or an EoE-related episode (e.g., an intervention for food impaction or stricture requiring dilatation) since last healthcare resource utilization assessment during the previous scheduled visit. Assessed at Week 24 and Week 52.

Time frame:
Week 24, Week 52
Reported as:
Count of participants · Participants
Percent of Patients With Relevant Concomitant Procedures and Healthcare Resource Utilization at Week 24 and Week 52.
ParticipantsBenralizumabPlacebo
Week 2435
Week 5202
SecondaryPatient Reported Overall Severity of Disease as Measured by Patient Global Impression of Severity (PGI-S) at Week 24

Patient Global Impression of Severity (PGI-S) is an assessment of the patient's perceived disease severity. The answer options are "no symptoms," "very mild," "mild," "moderate," "severe," and "very severe." The number analyzed represents the participants with evaluable PGI-S results at that timepoint.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Patient Reported Overall Severity of Disease as Measured by Patient Global Impression of Severity (PGI-S) at Week 24
ParticipantsBenralizumabPlacebo
No symptoms411
Very mild2327
Mild3432
Moderate2917
Severe36
Very Severe32
SecondaryPatient Reported Overall Severity of Disease as Measured by Patient Global Impression of Severity (PGI-S) at Week 52

Patient Global Impression of Severity (PGI-S) is an assessment of the patient's perceived disease severity. The answer options are "no symptoms," "very mild," "mild," "moderate," "severe," and "very severe." The number analyzed represents the participants with evaluable PGI-S results at that timepoint.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Patient Reported Overall Severity of Disease as Measured by Patient Global Impression of Severity (PGI-S) at Week 52
ParticipantsBenralizumabPlacebo
No symptoms610
Very mild1214
Mild913
Moderate85
Severe00
Very Severe10
SecondaryPatient Reported Change in Health Status Since Baseline as Measured by Patient Global Impression of Change (PGI-C) at Week 24

Patient Global Impression of Change (PGI-C) measures the patient's overall impression of response to treatment since the initial dose. The answer options are "much better," "moderately better," "a little better," "about the same/no change," "a little worse," "moderately worse," and "much worse." The number analyzed represents the participants with evaluable PGI-C results at that timepoint.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Patient Reported Change in Health Status Since Baseline as Measured by Patient Global Impression of Change (PGI-C) at Week 24
ParticipantsBenralizumabPlacebo
Much better1313
Moderately better1317
A little better2120
About the same3736
A little worse76
Moderately worse33
Much worse21
SecondaryPatient Reported Change in Health Status Since Baseline as Measured by Patient Global Impression of Change (PGI-C) at Week 52

Patient Global Impression of Change (PGI-C) measures the patient's overall impression of response to treatment since the initial dose. The answer options are "much better," "moderately better," "a little better," "about the same/no change," "a little worse," "moderately worse," and "much worse." The number analyzed represents the participants with evaluable PGI-C results at that timepoint.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Patient Reported Change in Health Status Since Baseline as Measured by Patient Global Impression of Change (PGI-C) at Week 52
ParticipantsBenralizumabPlacebo
Much better1213
Moderately better312
A little better812
About the same96
A little worse40
Moderately worse00
Much worse00
Other pre-specifiedBenralizumab Pharmacokinetics

Serum concentrations of benralizumab through Week 52. Geometric mean calculated using log transformed data.

Time frame:
Up to week 52
Reported as:
Geometric mean · ng/mL
Benralizumab Pharmacokinetics
ng/mLBenralizumabPlacebo
Week 81555.70 (1425.31 to 1698.02)—
Week 161582.46 (1322.66 to 1893.30)—
Week 241338.65 (1027.05 to 1744.78)NA (NA to NA)
Week 361405.94 (985.94 to 2004.86)1362.27 (1051.69 to 1764.58)
Week 521278.13 (749.19 to 2180.52)1495.61 (975.73 to 2292.50)
Other pre-specifiedImmunogenicity of Benralizumab in Double Blind Period

Immunogenicity of benralizumab assessed by ADA and nAb in the Double Blind period.

Time frame:
Up to Week 24
Reported as:
Number · Participants
Immunogenicity of Benralizumab in Double Blind Period
ParticipantsBenralizumabPlacebo
ADA positive/ADA prevalence (positive at baseline and/or post-baseline)188
ADA negative (negative at all assessments)8599
Treatment-emergent ADA positive/ADA incidence184
ADA persistently positive183
ADA positive subjects with maximum titre > median of maximum titres64
nAb positive/nAb prevalence100
ADA persistently positive and nAb positive100
Other pre-specifiedImmunogenicity of Benralizumab in Double Blind + Open Label Periods

Immunogenicity of benralizumab assessed by ADA and nAb in the Double Blind and Open Label periods.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Immunogenicity of Benralizumab in Double Blind + Open Label Periods
ParticipantsBenralizumabPlacebo
ADA positive/ADA prevalence (positive at baseline and/or post-baseline)1917
ADA negative (negative at all assessments)8488
Treatment-emergent ADA positive/ADA incidence1911
ADA persistently positive1610
ADA positive subjects with maximum titre > median of maximum titres77
nAb positive/nAb prevalence105
ADA persistently positive and nAb positive105
Other pre-specifiedSafety and Tolerability in Double Blind Period

Percentage of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Double Blind treatment period (up to Week 24).

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Safety and Tolerability in Double Blind Period
ParticipantsBenralizumabPlacebo
Any AE6666
Any SAE21
Other pre-specifiedSafety and Tolerability in the Open Label Period

Percentage of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Open Label treatment period (past week 24).

Time frame:
From Week 24 up to Week 52
Reported as:
Count of participants · Participants
Safety and Tolerability in the Open Label Period
ParticipantsBenralizumabPlacebo
Any AE5360
Any SAE24

Adverse events

Collected over On study AEs were collected from the first dose to the last date in study, up to 104 weeks.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg0/103 (0%)4/103 (3.9%)60/103 (58.3%)
Placebo0/107 (0%)1/107 (0.9%)42/107 (39.3%)
All Benra0/208 (0%)9/208 (4.3%)95/208 (45.7%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventBenra 30 mgPlaceboAll Benra
Oesophageal food impactionGastrointestinal disorders1/1030/1073/208
Infectious pleural effusionInfections and infestations1/1030/1071/208
Pneumonia bacterialInfections and infestations1/1030/1071/208
Affective disorderPsychiatric disorders1/1030/1071/208
DepressionPsychiatric disorders1/1030/1071/208
Disruptive mood dysregulation disorderPsychiatric disorders1/1030/1071/208
Oppositional defiant disorderPsychiatric disorders1/1030/1071/208
Suicide attemptPsychiatric disorders1/1030/1071/208
BronchospasmRespiratory, thoracic and mediastinal disorders1/1030/1071/208
AsthmaRespiratory, thoracic and mediastinal disorders0/1031/1070/208
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBenra 30 mgPlaceboAll Benra
COVID-19Infections and infestations34/10313/10749/208
NasopharyngitisInfections and infestations12/1036/10719/208
HeadacheNervous system disorders12/10311/10714/208
DiarrhoeaGastrointestinal disorders7/1033/10711/208
Oropharyngeal painRespiratory, thoracic and mediastinal disorders6/1031/1077/208
PharyngitisInfections and infestations5/1030/1075/208
AsthmaRespiratory, thoracic and mediastinal disorders5/1034/1079/208
Injection site erythemaGeneral disorders5/1032/1077/208
Upper respiratory tract infectionInfections and infestations4/1035/1078/208
Back painMusculoskeletal and connective tissue disorders4/1030/1076/208

Baseline characteristics

All participants who were randomized and received any IP were included in the full analysis set.

Age, Continuous
Age, Continuous(years)BenralizumabPlaceboTotal
Mean33.9 ± 13.4933.6 ± 12.7333.7 ± 13.08
Age, Customized
Age, Customized(Participants)BenralizumabPlaceboTotal
< 18 years old141428
18-21 years old111122
22-35 years old323567
>= 36 years old464793
Age, Customized
Age, Customized(Participants)BenralizumabPlaceboTotal
<= 21 years old252550
> 21 years old7882160
Sex: Female, Male
Sex: Female, Male(Participants)BenralizumabPlaceboTotal
Female312253
Male7285157
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BenralizumabPlaceboTotal
Black or African American112
White9796193
Native Hawaiian or other Pacific Islander011
American Indian or Alaska Native000
Asian257
Other314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BenralizumabPlaceboTotal
Hispanic or Latino61016
Non-Hispanic or Latino9794191
08

Study locations

78 sites
  • Research Site
    Little Rock, Arkansas 72202, United States
  • Research Site
    Saint Petersburg, Florida 33709, United States
  • Research Site
    Atlanta, Georgia 30322-1013, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Park Ridge, Illinois 60068, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Chesterfield, Michigan 48047, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Ocean City, New Jersey 07712, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Chapel Hill, North Carolina 27514, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Uniontown, Pennsylvania 15401, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    Salt Lake City, Utah 84132, United States
  • Research Site
    Richmond, Virginia 23219, United States
  • Research Site
    Hamilton, Ontario L8S 1G5, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Ottawa, Ontario K1H 1E4, Canada
  • Research Site
    Windsor, Ontario N8X 2G1, Canada
  • Research Site
    Dijon Cedex, 21079, France
  • Research Site
    Lille Cedex, 59037, France
  • Research Site
    Lille, F-59037, France
  • Research Site
    Lyon Cedex 03, 69437, France
  • Research Site
    Pessac, 33600, France
  • Research Site
    Suresnes Cedex, 92151, France
  • Research Site
    Toulouse Cedex 9, 31059, France
  • Research Site
    Frankfurt, 60590, Germany
  • Research Site
    München, 80337, Germany
  • Research Site
    München, 81675, Germany
  • Research Site
    Remscheid, 42859, Germany
  • Research Site
    Afula, 18341, Israel
  • Research Site
    Holon, 58100, Israel
  • Research Site
    Kfar-Saba, 4428164, Israel
  • Research Site
    Petach-Tikva, 4920235, Israel
  • Research Site
    Tel Aviv, 64239, Israel
  • Research Site
    Firenze, 50134, Italy
  • Research Site
    Genova, 16126, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Chiba-Shi, 260-0877, Japan
  • Research Site
    Izumo-shi, 693-8501, Japan
  • Research Site
    Maebashi-shi, 371-8511, Japan
  • Research Site
    Osaka-shi, 545-8586, Japan
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Nieuwegein, 3435 CM, Netherlands
  • Research Site
    Nijmegen, 6525 GA, Netherlands
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Knurów, 44-190, Poland
  • Research Site
    Lublin, 20-582, Poland
  • Research Site
    Rzeszow, 35-302, Poland
  • Research Site
    Szczecin, 71-434, Poland
  • Research Site
    Warszawa, 04-141, Poland
  • Research Site
    Wrocław, 50-449, Poland
  • Research Site
    Łódź, 93-338, Poland
  • Research Site
    Chelyabinsk, 454091, Russian Federation
  • Research Site
    Moscow, 105066, Russian Federation
  • Research Site
    Moscow, 111123, Russian Federation
  • Research Site
    Moscow, 119992, Russian Federation
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Bilbao, 48013, Spain
  • Research Site
    Madrid, 28006, Spain
  • Research Site
    Madrid, 28031, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Brighton, BN2 5BE, United Kingdom
  • Research Site
    Darlington, DL3 6HX, United Kingdom
  • Research Site
    London, E1 2AJ, United Kingdom
  • Research Site
    London, SW17 0RE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Sep 2022, 23 months.

Results were first posted in Nov 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Sep 10, 2020
StartActual
Sep 22, 2020
Primary completionActual
Sep 19, 2022
CompletionActual
Feb 6, 2023
Results first posted
Nov 18, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04543409
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Sep 22, 2020
Primary completion
Sep 19, 2022
Completion
Feb 6, 2023
Results posted
Nov 18, 2023
Last update
Nov 18, 2023

Study contacts

Marc E. Rothenberg, MD, PhD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion